



IFSO SESSION

DECISION MAKING IN MBS: TIME FOR A CHANGE?



Director
Gerhard Prager



Co-Director
Jaime Ponce

Review of recent evidence on recently endorsed procedures and adjuvant management with anti-obesity medications from the worldwide experience standpoint, including the impact and level of evidence of new 2022 ASMBBS/IFSO guidelines. The session should be of great interest to clinicians at all levels of experience.

LEARNING OBJECTIVES

- Understand the management options with the use of Obesity Management Medications and Metabolic Bariatric Surgery
- Review recent Randomized Clinical Trials and implications
- Learn the level of evidence and impact of the new 2022 ASMBBS/IFSO guidelines
- Learn the effects of obesity treatments in cardiovascular risk reduction